Re-irradiation of locally recurrent pediatric intracranial ependymoma: Experience of the French society of children's cancer.


Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
03 2019
Historique:
received: 11 08 2017
revised: 12 11 2018
accepted: 13 11 2018
entrez: 4 3 2019
pubmed: 4 3 2019
medline: 29 1 2020
Statut: ppublish

Résumé

This study aimed to evaluate retrospectively the clinical results of re-irradiation for children with a locally recurrent brain ependymoma. 33 full-dose re-irradiations were delivered to 31 children with a recurrent brain ependymoma after a standard treatment. Each child was followed up with clinical and MRI examinations. We evaluated overall survival, local recurrence free-survival and short term toxicity according to CTCAE 4.0 scale. With a median follow-up of 37 months (range, 0 to 107), median local recurrence free-survival was 31 months (range, 2 to 63) and median overall survival was 34 months (range, 3 to 63). It was significantly higher in patients who underwent surgery first, compared with re-irradiation only. Cumulated dosimetric data were available for 22 patients. On average, maximal BED to brain stem was 106,2 Gy Local recurrence of brain ependymoma can be treated with full-dose re-irradiation, which can be hypofractionated with an acceptable short term toxicity in spite of high total doses delivered to OARs, especially brain stem.

Identifiants

pubmed: 30825956
pii: S0167-8140(18)33601-6
doi: 10.1016/j.radonc.2018.11.009
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-7

Informations de copyright

Copyright © 2018. Published by Elsevier B.V.

Auteurs

Elise Régnier (E)

Radiation Oncology Institut Jean Godinot, Reims Cedex, France. Electronic address: eregnier@ch-annecygenevois.fr.

Anne Laprie (A)

Oncology Radiotherapy, Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France.

Anne Ducassou (A)

Oncology Radiotherapy, Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France.

Stéphanie Bolle (S)

Oncology Radiotherapy Institut Gustave Roussy, Villejuif, France.

Stéphane Supiot (S)

Oncology Radiotherapy, ICO René Gauducheau, Saint Herblain, France.

Xavier Muracciole (X)

Oncology Radiotherapy Hopital de la Timone, Marseille Cedex, France.

Line Claude (L)

Oncology Radiotherapy t, Centre Léon Bérard, Lyon, France.

Sophie Chapet (S)

Oncology Radiotherapy CHRU Bretonneau, Tours, France.

Bernard Coche-Dequéant (B)

Oncology Radiotherapy Centre Oscar Lambret, Lille, France.

Céline Vigneron (C)

Oncology Radiotherapy Centre Paul Strauss, Strasbourg, France.

Julie Leseur (J)

Oncology Radiotherapy Centre Eugène Maquis, Rennes, France.

Pierre Y Bondiau (PY)

Oncology Radiotherapy Centre Antoine Lacassagne, Nice, France.

Jean L Habrand (JL)

Oncology Radiotherapy Centre François Baclesse, Caen, France.

Valérie Bernier (V)

Oncology Radiotherapy Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH